Cygnal Therapeutics to Develop Drugs Based on Exoneural Biology
- Posted by ISPE Boston
- On October 10, 2019
Flagship Pioneering has unveiled Cambridge-based Cygnal Therapeutics which was founded in 2017 in Flagship Labs. Cygnal is the first company to develop drugs in the field of exoneural biology, a new understanding of how nerves and neural signaling drive human health and disease. The company has discovered biologically relevant pathways and advanced starting points for […]
Read More